Ideanomics, Inc. Reports Q4 and Full Year 2022 Financial Results
Get Alerts IDEX Hot Sheet
Join SI Premium – FREE
Company achieves consecutive revenue growth from the sale of EV and Charging Solutions for the third year in a row
"Last year was challenging for the entire EV industry. Despite the headwinds,
Highlights
- VIA Motors secured a
$170 million order with Pegasus Specialty Vehicles and established a partnership with EAVX (part of JB Poindexter) to develop an electric class 2b delivery van. - Combined, Solectrac and Energica sold more than 850 branded electric vehicles. Solectrac established a
U.S. coast-to-coast certified dealer network, and Energica reached 140 certified dealerships across five continents. - Announced high-value commercial deals including the delivery of 88 Energica motorcycles to the
Indonesia National Police , US Hybrid supplying power train solutions for 62 zero-emission street sweepers, and a WAVE inductive wireless charging project with a major e-commerce company.
Ideanomics Full Year 2022 Operating Results
Revenue for the Full Year was
Gross Profit
Gross profit for the Full Year was negative
Conference Call Information
To join the webcast, please visit the 'Events & Presentations' section of the
About
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the federal securities laws. All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, involve known and unknown risks and uncertainties, and include the statement regarding the completion of the business combination within a certain period of time, if ever. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of risks and uncertainties, such as risks related to: our ability to obtain necessary regulatory approvals and other risks and uncertainties disclosed under the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent Form 10-K and Form 10-Q filed with the
Investor Relations and Media Contact
Ideanomics,Inc.
Email: [email protected]
Theodore Rolfvondenbaumen
Communications Director
Email: [email protected]
As of | 2022 | 2021 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | ||||
Accounts receivable, net | 5,855 | 3,338 | ||
Contract assets | 3,579 | 2,772 | ||
Amount due from related parties | 899 | 266 | ||
Notes receivable from third parties, net | 31,653 | 54,907 | ||
Notes receivable from related party | — | 697 | ||
Inventory | 28,246 | 6,159 | ||
Prepaid expenses | 13,341 | 20,015 | ||
Other current assets | 8,536 | 4,490 | ||
Total current assets | 114,038 | 362,507 | ||
Property and equipment, net | 9,072 | 2,905 | ||
Intangible assets, net | 52,768 | 42,546 | ||
37,775 | 16,161 | |||
Operating lease right of use assets | 15,979 | 12,827 | ||
Financing lease right of use assets | 1,565 | — | ||
Long-term investments | 10,284 | 35,588 | ||
Other non-current assets | 1,320 | 903 | ||
Total assets | ||||
LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND EQUITY | ||||
Current liabilities | ||||
Accounts payable | ||||
Deferred revenue (including customer deposits of | 2,749 | 5,392 | ||
Accrued salaries | 9,848 | 8,957 | ||
Amount due to related parties | 2,376 | 1,102 | ||
Other current liabilities | 13,676 | 7,137 | ||
Current portion of operating lease liabilities | 4,082 | 3,086 | ||
Current portion of financing lease liabilities | 345 | — | ||
Current contingent consideration | 867 | 648 | ||
Promissory note due to related party-short term | 2,021 | — | ||
Promissory note due to third parties-short term | 7,270 | 312 | ||
Convertible promissory note due to third-parties | 3,928 | 57,809 | ||
Total current liabilities | 76,861 | 91,117 | ||
Promissory note-long term | 1,957 | — | ||
Operating lease liability-long term | 12,273 | 9,647 | ||
Financing lease liabilities-long term | 1,188 | — | ||
Non-current contingent liabilities | — | 350 | ||
Deferred tax liabilities | 3,000 | 5,073 | ||
Other long-term liabilities | 959 | 620 | ||
Total liabilities | 96,238 | 106,807 | ||
Commitments and contingencies (Note 19) | ||||
Convertible redeemable preferred stock: | ||||
Series A - 7,000,000 shares issued and outstanding, liquidation and deemed liquidation preference of | 1,262 | 1,262 | ||
Series B - 5,000,000 shares issued and outstanding | 8,850 | — | ||
Equity: | ||||
Common stock - | 597 | 497 | ||
Additional paid-in capital | 1,004,082 | 968,066 | ||
Accumulated deficit | (866,450) | (605,758) | ||
Accumulated other comprehensive (income) loss | (6,104) | 222 | ||
132,125 | 363,027 | |||
Non-controlling interest | 4,326 | 2,341 | ||
Total equity | 136,451 | 365,368 | ||
Total liabilities, convertible redeemable preferred stock and equity | ||||
The accompanying notes are an integral part of these consolidated financial statements. |
For the years ended | 2022 | 2021 | 2020 | |||
Revenue from sales of products (including from a related party of | ||||||
Revenue from sales of services | 36,070 | 75,766 | 1,631 | |||
Other revenue | 414 | 1,305 | — | |||
Total revenue | 100,936 | 114,080 | 26,759 | |||
Cost of revenue from sales of products (including from a related party of | 72,047 | 37,845 | 23,644 | |||
Cost of revenue from sales of services | 29,330 | 51,562 | 1,058 | |||
Cost of other revenue | 374 | 1,445 | — | |||
Total cost of revenue | 101,751 | 90,852 | 24,702 | |||
Gross profit | (815) | 23,228 | 2,057 | |||
Operating expenses: | ||||||
Selling, general and administrative expenses | 148,678 | 107,535 | 44,940 | |||
Research and development expense | 3,888 | 760 | 1,635 | |||
Asset impairments | 91,333 | 71,070 | 33,230 | |||
38,868 | 101,470 | 18,089 | ||||
Change in fair value of contingent consideration, net | (131) | (9,600) | (5,503) | |||
Litigation settlements | 1,362 | 5,432 | — | |||
Depreciation and amortization | 7,717 | 6,118 | 5,310 | |||
Total operating expenses | 291,715 | 282,785 | 97,701 | |||
Loss from operations | (292,530) | (259,557) | (95,644) | |||
Interest and other income (expense): | ||||||
Interest income | 3,504 | 1,502 | 108 | |||
Interest expense | (2,950) | (2,139) | (16,078) | |||
Expense due to conversion of notes | — | — | (2,266) | |||
Gain on extinguishment of debt | — | 300 | 8,891 | |||
(Loss) Gain on disposal of subsidiaries, net | (276) | (1,264) | 276 | |||
Gain on remeasurement of investment | 10,965 | 2,915 | — | |||
Other income, net | 6,478 | 1,261 | 6,604 | |||
Loss before income taxes and non-controlling interest | (274,809) | (256,982) | (98,109) | |||
Income tax benefit | 7,711 | 11,786 | 3,308 | |||
Impairment of and equity in loss of equity method investees | (15,018) | (11,529) | (16,780) | |||
Net loss | (282,116) | (256,725) | (111,581) | |||
Deemed dividend related to warrant repricing | — | — | (184) | |||
Net loss attributable to common shareholders | (282,116) | (256,725) | (111,765) | |||
Net loss attributable to non-controlling interest | 21,424 | 716 | 10,501 | |||
Net loss attributable to | ||||||
Basic and diluted loss per share | ||||||
Weighted average shares outstanding: | ||||||
Basic and diluted | 512,702,986 | 447,829,204 | 213,490,535 | |||
The accompanying notes are an integral part of these consolidated financial statements. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideanomics-inc-reports-q4-and-full-year-2022-financial-results-301785307.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health revises 2025 non-GAAP figures after SEC staff talks
- Novartis pelacarsen trial fails; Royalty Pharma expects modest return
- Bergeron files proxy to challenge Ethan Allen board at 2026 meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share